DBV Technologies Q1 2023 Earnings Report $3.21 -0.01 (-0.31%) (As of 12/17/2024 05:56 PM ET) Earnings HistoryForecast DBV Technologies EPS ResultsActual EPS-$1.10Consensus EPS -$2.50Beat/MissBeat by +$1.40One Year Ago EPSN/ADBV Technologies Revenue ResultsActual Revenue$2.19 millionExpected Revenue$1.30 millionBeat/MissBeat by +$890.00 thousandYoY Revenue GrowthN/ADBV Technologies Announcement DetailsQuarterQ1 2023Date5/4/2023TimeN/AConference Call ResourcesConference CallDBVT Earnings History Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. DBV Technologies Earnings HeadlinesDBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.comDecember 16 at 2:08 AM | americanbankingnews.comDBV Technologies Aligns with FDA for Viaskin Peanut ApprovalDecember 13, 2024 | markets.businessinsider.comAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDecember 18, 2024 | Crypto 101 Media (Ad)DBV jumps 52% to $4.99 after aligning with FDA on approval pathwayDecember 12, 2024 | markets.businessinsider.comDBV Technologies announces FDA alignment on Viaskin Peanut patch program pathwayDecember 12, 2024 | markets.businessinsider.comStocks to Watch: Adobe, Champions Oncology, DBV TechnologiesDecember 11, 2024 | marketwatch.comSee More DBV Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email. Email Address About DBV TechnologiesDBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.View DBV Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
